Diagnostics Industry

Found 5,934 articles

• Autism-Focused Life Sciences Company Revolutionizes the Diagnostic Journey for Families Nationwide

  1/3/2024

  Quadrant Biosciences has reached a new milestone in their quest to provide integrated solutions to families who, for decades, have been navigating a very fractured health system surrounding autism services.

• SEKISUI Diagnostics and Aptitude Partner to Provide Metrix™ COVID-19 Tests to the Point-of-Care and Home Test Markets

  1/3/2024

  SEKISUI Diagnostics, a global medical diagnostics manufacturer, has formalized an exclusive distribution agreement with Aptitude Medical Systems (Aptitude™), an innovative developer of decentralized molecular diagnostics, to sell the Aptitude Metrix™ COVID-19 Test in the U.S.

• Enable Biosciences Inc. Reveals Key Findings on COVID-19 Transmission from Mothers to Newborns

  1/3/2024

  Enable Biosciences Inc. has achieved a breakthrough in understanding maternal SARS-CoV-2 infection and its impact on newborns.

• QIAGEN expands business in Middle East with new regional headquarters and major projects

  1/3/2024

  QIAGEN announced a significant expansion of its business in the Middle East region, which includes three major developments.

• Baylor Genetics Accelerates Growth, Combines Clinical and Scientific Expertise with Commercial Capabilities to Meet Increased Needs of Patients, Providers and Partners

  1/3/2024

  Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, continued to accelerate its market leadership and growth over the last 12 months, expanding its test menu, commercial reach, lab operations, technology, and customer experience initiatives.

• AnX Robotica Announces FDA Clearance for ProScan™: A Groundbreaking AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy

  1/3/2024

  AnX Robotica, a pioneering force in advanced gastrointestinal visualization technologies, is excited to announce the FDA clearance of NaviCam ProScan™.

• EarlyDiagnostics, Inc. Appoints Gregory C. Critchfield, M.D. M.S., as Co-CEO

  1/3/2024

  EarlyDiagnostics, the leading company in world-class liquid biopsy methylome detection of early cancer announced the appointment of Gregory Critchfield as Co-CEO, effective January 1, 2024.

• Co-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12

  1/3/2024

  Co-Diagnostics, Inc. announced that it will be hosting a booth next week at the 2024 Consumer Electronics Show from January 9-12 in Las Vegas, Nevada.

• Precipio Announces Christina Valauri joins the Board of DirectorsDouglas Fisher, MD will step down as Director, and remain as a board observer

  1/2/2024

  Specialty cancer diagnostics company Precipio, Inc. is pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024.

• Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

  1/2/2024

  Bluejay Diagnostics, Inc. announced the closing of its previously announced public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.

• LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

  12/29/2023

  LumiraDx Limited, a next generation point of care diagnostics company, announced the appointment of joint administrators for two of its subsidiaries.

• Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

  12/28/2023

  Bluejay Diagnostics, Inc. announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.

• Seegene obtains ISO45001 certification

  12/27/2023

  Seegene Inc. announced that it has achieved an ISO45001 certification on December 27.

• CCM Biosciences Announces Launch of 5Prime Sciences Business Unit

  12/27/2023

  Diversified biotechnology company CCM Biosciences announced the launch of its business unit CCM 5Prime Sciences focused on the development and application of proprietary technology in the domain of DNA biotechnology.

• Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

  12/27/2023

  Co-Diagnostics, Inc. announced that it has submitted its Co-Dx™ PCR COVID-19 test with Co-Dx PCR Pro™ instrument for review by the U.S. Food and Drug Administration for Emergency Use Authorization.

• Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

  12/27/2023

  Bluejay Diagnostics, Inc., announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients.

• RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its IRB to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

  12/26/2023

  RetinalGeniX™ Technologies Inc., announced that it has contracted with MEDsan, Inc. to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on October 30, 2023.

• Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

  12/20/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the launch of the Myriad Collaborative Research Registry™.

• Meilleur Technologies Inc. Announces Execution of Manufacturing Agreement with PharmaLogic for Production of the Next-Generation Amyloid PET Imaging Biomarker, NAV4694

  12/20/2023

  Meilleur Technologies Inc. announced it has signed an agreement with PharmaLogic Holdings Corporation granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography imaging studies to assess the status of amyloid plaque in the brain.

• AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production

  12/20/2023

  AXIM Biotechnologies, Inc. announced that the Company has signed an agreement with contract manufacturer Auer Precision for the production of its two FDA-cleared diagnostic assays designed for point-of-care diagnosis of Dry Eye Disease.